Form 8-K Hims & Hers Health, Inc. For: Jun 26
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/7/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Hims & Hers units enter $400M receivables deal with JPMorgan
July 1, 2026 5:04 PM EDTSubsidiaries of Hims & Hers Health, Inc. (NYSE: HIMS) entered into a receivables purchase agreement with JPMorgan Chase Bank, N.A. on July 1, 2026, according to a regulatory filing.
XeCare LLC and Apostrophe Pharmacy LLC, both subsidiaries of Hims & Hers, signed a Master Receivables Purchase Agreement that allows them to sell eligible receivables... More
